Effects of recombinant granulocyte-colony stimulating factor administration during Mycobacterium avium infection in mice

Clinical and Experimental Immunology

Volumn 124, Issue 2, 2001, Pages 239-247

  Goncalves A S ^a   Appelberg, R ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

AIDS animal models; Immunotherapy; Mycobacterium avium complex; Neutrophils

Indexed keywords

CLARITHROMYCIN; ETHAMBUTOL; GAMMA INTERFERON; INTERLEUKIN 10; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIFABUTIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BACTERIAL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; GENE DISRUPTION; IMMUNOTHERAPY; LEUKOCYTE COUNT; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; NEUTROPHILIA; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTITUBERCULAR AGENTS; BLOOD PROTEINS; CLARITHROMYCIN; ETHAMBUTOL; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; INTERFERON TYPE II; INTERLEUKIN-10; MICE; MICE, INBRED C57BL; MYCOBACTERIUM AVIUM; NEUTROPHILS; RIFABUTIN; TUBERCULOSIS;

EID: 0034951764     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2001.01552.x     Document Type: Article

References (50)

1. Disease due to the Mycobacterium avium complex in patients with AIDS, epidemiology and clinical syndrome
2. Natural history of disseminated Mycobacterium avium complex infection in AIDS
3. The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients - A prospective study
4. Predictors of survival in patients with AIDS and disseminated Mycobacterium avium complex disease
5. Geographical and seasonal variation in Mycobacterium avium bacteremia among North American patients with AIDS
6. An epidemiologic analysis of Mycobacterium avium complex disease in homosexual men infected with human immunodeficiency virus type 1
7. Disseminated Mycobacterium avium complex disease in the Swiss HIV Cohort Study: Increasing incidence, unchnaged prognosis
8. Trends in AIDS-related opportunistic infections among men who have sex with men and among injecting drug users, 1991-96
9. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
10. Immune response to atypical mycobacteria
11. Neutrophil-macrophage cooperation in the host defense against mycobacterial infections
12. Susceptibility of beige mice to Mycobacterium avium: Role of neutrophils
13. Depressed neutrophil superoxide production in human immunodeficiency virus infection
14. Impairment of neutrophil antifungal activity against hyphae of Aspergiffus fumigatus in children infected with human immunodeficiency virus
15. Granulocyte-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils
16. Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection
17. Neutropenia is associated with bacteremia in patients infected with the human immunodeficiency virus
18. Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS
19. Cytokines enhance neutrophils from human immunodeficiency virus-negative donors and AIDS patients to inhibit the growth of Mycobacterium avium in vitro
20. Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57B1/6 mice
21. Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin™) stimulates neutrophils and tissue macrophages and induces an effective non-specific response against Mycobacterium avium in mice
22. Neupogen (filgrastim) use is associated with prolonged survival in HIV-infected patients with disseminated Mycobacterium avium complex infection
23. Rapid clearance of Mycobacterium avium from the blood of nonneutropenic AIDS patients treated with G-CSF (Filgrastim) and antimycobacterial therapy
24. Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients
25. Filgrastim prevents severe neutropenia and reduced infective morbidity in patinets with advanced HIV infection: Results of a randomized, multicenter, controlled trial
26. The role of gamma interferon and tumor necrosis factor-alpha during the T cell independent and dependent phases of Mycobacterium avium infection
27. Chronic neutropenia. A new canine model induced by human granulocyte colony-stimulating factor
28. Characterization of the virulence of Mycobacterium avium complex isolates in mice
29. Relationship between virulence of Mycobacterium avium strains and induction of tumor necrosis factor-α production in infected mice and in vitro-cultured mouse macrophages
30. Involvement of reactive oxygen intermediates in the tumor necrosis factor-dependent bacteriostasis of Mycobacterium avium
31. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease
32. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers
33. Infection with Mycobacterium avium induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice
34. Enhanced interleukin-10 production in response to Mycobacterium avium products in mononuclear cells from patients with human immunodeficiency virus infection
35. Prostaglandin E2 primes naive T cells for the production of anti-inflammatory cytokines
36. Granulocyte colony-stimulating factor - Role and relationships in infectious diseases
37. Synergy of simultaneous administration of ofloxacin and granulocyte colony-stimulating factor in killing of Escherichia coli by human neutrophils
38. Combined effect of human neutrophils, ceftazidime and granulocyte colony-stimulating factor on killing of Escherichia coli
39. Protective effect of granulocyte colony-stimulating factor (G-CSF) in a granulocytopenic mouse model of Pseudomonas aeruginosa lung infection through enhanced phagocytosis and killing by alveolar macrophages through priming tumour necrosis factor-alpha (TNF-α) production
40. Protective effect of human granulocyte colony-stimulating factor on microbial infection in neutropenic mice
41. Effects of granulocyte and granulocyte-macrophage colony-stimulating factors in a neutropenic murine model of trichosporonosis
42. Granulocyte colony stimulating factor worsens the outcome of experimental Klebsiella pneumoniae pneumonia through direct interaction with the bacteria
43. The international epidemiology of disseminated Mycobacterium avium complex infection in AIDS
44. G-CSF association with prolonged survival in HIV-infected patients with disseminated Mycobacterium avium complex infection
45. Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-α
46. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: A mechanism for monocyte-mediated suppression of T-cell proliferation
47. Granulocyte colony-stimulating factor downregulates allogeneic immune responses by posttranscriptional inhibition of tumor necrosis factor-α production
48. Giant granules of neutrophils in Chediak-Higashi syndrome are derived from azurophil granules but not from specific and gelatinase granules
49. Identification of the homologous beige and Chediak-Higashi syndrome genes
50. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection